Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week treat-to-target trial of insulin degludec/insulin aspart vs insulin glargine in type 2 diabetes
2009-017814-56Phase 3Suspended
- Sponsor
- Novo Nordisk
- Start
- Dec 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c at 26 weeks. Started Dec 2010; status: suspended.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-017814-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017814-56.